This is a multi-centre, observational, non-interventional study. Patients with metastatic colorectal cancer eligible for Bevacizumab in combination with chemotherapy treatment will be enrolled in this trial.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
with histologically confirmed metastatic colorectal cancer
patients with metastatic colorectal cancer who are eligible for Bevacizumab in combination with chemotherapy treatment
Written informed consent
Unlimited line of treatment (first-line or second line is not limited)
You may not be if
Recent history of serious hemorrhage or hemoptysis of ≥1/2 teaspoon of red blood
Proteinuria at baseline: Patients discovered to have ≥ 2 grams of proteinuria/24 hours \*
* The measurement of 24-hour proteinuria level is recommended for patients with moderate to high proteinuria risk indicated by clinical judgement. The treatment with bevacizumab should be delayed when proteinuria is ≥2g/24 hours.
Major surgical procedure within 28 days prior to treatment initiation, or not fully healed wounds
Pregnant or lactating women
Excluding patients known to be allergic to bevacizumab or any of the excipients
Clareo Health | Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer
